Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.40 |
| ▸ | NPY1R | P25929 | 7/20 | 0.40 |
| ▸ | NPY2R | P49146 | 5/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011349 | 1.00 | NPY4R (0.40) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL27732271 | 1.00 | NPY4R (0.40) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30111320 | 0.97 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31265334 | 0.95 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30484000 | 0.94 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31318675 | 0.94 | ENPEP (0.47) | ENPEP | |
| SCHEMBL19554383 | 0.94 | NPY4R (0.39) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31410877 | 0.93 | ENPEP (0.40) | NPY4RNPY1RNPY2RNPY5RENPEP | |
| SCHEMBL31206444 | 0.93 | ENPEP (0.47) | NPY4RNPY1RNPY2RNPY5RENPEP | |
| Trifluoroacetic Acid SCHEMBL7445661 | 0.93 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12449424-B2 | In vitro method for detecting avian intestinal dysbiosis | EVONIK OPERATIONS GMBH (DE) | 2025-10-21 | — | — | US | claimed |
| CN-119874813-A | Short peptide compound and preparation method thereof, cosmetic composition and application | 常州市智态生创科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119752821-A | Enzyme mutant and application thereof in preparation of isoleucyl arginine | 深圳瑞德林生物技术有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-118515729-A | Design, preparation and application of novel chimeric peptides and analogues thereof based on Kappa opioid peptide agonist | 兰州大学 | 2024-08-20 | — | — | CN | claimed |
| CN-113167803-B | In-vitro detection method for intestinal dysbiosis of poultry | 赢创运营有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-117203325-A | Glycoside product biosynthesis and recovery | 马努斯生物合成股份有限公司 | 2023-12-08 | — | — | CN | claimed |
| EP-4251731-A1 | GLYCOSIDE PRODUCT BIOSYNTHESIS AND RECOVERY | Manus Bio Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| EP-3894863-B1 | IN VITRO METHOD FOR DETECTING AVIAN INTESTINAL DYSBIOSIS | EVONIK OPERATIONS GMBH (DE) | 2022-11-23 | — | — | EP | claimed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| WO-2022115527-A1 | GLYCOSIDE PRODUCT BIOSYNTHESIS AND RECOVERY | MANUS BIO INC. (US) | 2022-06-02 | — | — | WO | claimed |
| US-20220050115-A1 | IN VITRO METHOD FOR DETECTING AVIAN INTESTINAL DYSBIOSIS | EVONIK OPERATIONS GMBH (DE) | 2022-02-17 | — | — | US | claimed |
| EP-3894863-A1 | IN VITRO METHOD FOR DETECTING AVIAN INTESTINAL DYSBIOSIS | Evonik Operations GmbH (DE) | 2021-10-20 | — | — | EP | claimed |
| WO-2020120376-A1 | IN VITRO METHOD FOR DETECTING AVIAN INTESTINAL DYSBIOSIS | EVONIK OPERATIONS GMBH (DE) | 2020-06-18 | — | — | WO | claimed |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-07 | — | — | US | disclosed |
| US-5157022-A | Administering arginine nicotinate and di- and tripeptides of arginine | BARBUL ADRIAN (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0502007-A1 | ARGININE NICOTINATE FOR REDUCING BLOOD CHOLESTEROL | BARBUL, Adrian (US) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007188-A1 | METHOD FOR REDUCING BLOOD CHOLESTEROL USING ARGININE | BARBUL ADRIAN (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | NPY4R 519/4885NPY1R 1058/4885NPY2R 1056/4885 |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | SLC7A1, TAP1, SLC7A5 | NPY4R 3861/4885NPY1R 3185/4885NPY2R 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.